Provectus Biopharmaceuticals Stock Gross Profit
PVCTDelisted Stock | USD 0.11 0.00 0.00% |
Provectus Biopharmaceuticals fundamentals help investors to digest information that contributes to Provectus Biopharmaceutica's financial success or failures. It also enables traders to predict the movement of Provectus OTC Stock. The fundamental analysis module provides a way to measure Provectus Biopharmaceutica's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Provectus Biopharmaceutica otc stock.
Provectus |
Provectus Biopharmaceuticals OTC Stock Gross Profit Analysis
Provectus Biopharmaceutica's Gross Profit is the most basic measure of business operational efficiency. It is simply the difference between sales revenue and the cost associated with making a product or providing a service. It is calculated before deducting administrative expenses, taxes, and interest payments.
Gross Profit varies significantly from one sector to another and tells an investor how much money a business would have made if it didn't have to pay any overhead expenses such as salary, taxes, or rent.
CompetitionAccording to the company disclosure, Provectus Biopharmaceuticals reported 0.0 of gross profit. This is 100.0% lower than that of the Pharmaceuticals sector and 100.0% lower than that of the Health Care industry. The gross profit for all United States stocks is 100.0% higher than that of the company.
Provectus Gross Profit Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Provectus Biopharmaceutica's direct or indirect competition against its Gross Profit to detect undervalued stocks with similar characteristics or determine the otc stocks which would be a good addition to a portfolio. Peer analysis of Provectus Biopharmaceutica could also be used in its relative valuation, which is a method of valuing Provectus Biopharmaceutica by comparing valuation metrics of similar companies.Provectus Biopharmaceutica is currently under evaluation in gross profit category among its peers.
Provectus Fundamentals
Return On Asset | -1.85 | ||||
Operating Margin | (4.77) % | ||||
Current Valuation | 46.73 M | ||||
Shares Outstanding | 419.55 M | ||||
Shares Owned By Insiders | 3.69 % | ||||
Shares Owned By Institutions | 0.04 % | ||||
Number Of Shares Shorted | 1.82 M | ||||
Price To Earning | (0.48) X | ||||
Price To Book | 5.44 X | ||||
Price To Sales | 55.94 X | ||||
EBITDA | (4.56 M) | ||||
Net Income | (5.54 M) | ||||
Cash And Equivalents | 84.27 K | ||||
Total Debt | 2.29 M | ||||
Debt To Equity | 0.25 % | ||||
Current Ratio | 0.27 X | ||||
Book Value Per Share | (0.02) X | ||||
Cash Flow From Operations | (1.01 M) | ||||
Short Ratio | 0.47 X | ||||
Earnings Per Share | (0.01) X | ||||
Target Price | 3.5 | ||||
Beta | 0.5 | ||||
Market Capitalization | 44.47 M | ||||
Total Asset | 3.51 M | ||||
Retained Earnings | (180.8 M) | ||||
Working Capital | 10.6 M | ||||
Current Asset | 14.72 M | ||||
Current Liabilities | 4.12 M | ||||
Z Score | -59.7 | ||||
Net Asset | 3.51 M |
About Provectus Biopharmaceutica Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Provectus Biopharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Provectus Biopharmaceutica using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Provectus Biopharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this otc stock, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any otc stock could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators. Note that the Provectus Biopharmaceutica information on this page should be used as a complementary analysis to other Provectus Biopharmaceutica's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Stock Screener module to find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook..
Other Consideration for investing in Provectus OTC Stock
If you are still planning to invest in Provectus Biopharmaceutica check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Provectus Biopharmaceutica's history and understand the potential risks before investing.
Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
CEOs Directory Screen CEOs from public companies around the world | |
Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals |